Provided by Tiger Trade Technology Pte. Ltd.

Instil Bio, Inc.

7.99
+0.21002.70%
Post-market: 7.990.00000.00%16:10 EST
Volume:40.39K
Turnover:319.55K
Market Cap:54.19M
PE:-0.70
High:8.10
Open:7.83
Low:7.63
Close:7.78
52wk High:42.79
52wk Low:5.67
Shares:6.78M
Float Shares:3.31M
Volume Ratio:1.14
T/O Rate:1.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.3683
EPS(LYR):-11.3876
ROE:-50.60%
ROA:-14.91%
PB:0.45
PE(LYR):-0.70

Loading ...

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

GlobeNewswire
·
Feb 12

TIL Limited Converts Warrants, Raises Paid-Up Equity Capital to Rs. 70.35 Crore

TIPRANKS
·
Jan 29

Cellectis Announces 2026 Strategy and Catalysts

GlobeNewswire
·
Jan 09

Instil Bio Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
Jan 07

Instil Bio, Inc. : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
Jan 07

U.S. RESEARCH ROUNDUP-Alphabet, Hershey, Micron Technology

Reuters
·
Jan 07

Instil Bio Inc : Baird Cuts to Neutral From Outperform; Cuts Target Price to $7 From $180 to Reflect Approximate Cash Value

THOMSON REUTERS
·
Jan 07

Instil Bio Pulls Plug On Lead Drug Development

Benzinga_recent_news
·
Jan 07

Instil Bio Subsidiary Axion Bio Halts AXN-2510 Clinical Development

Reuters
·
Jan 06

Instil Bio Inc - Rights Licensed to Axion Revert to ImmuneOnco

THOMSON REUTERS
·
Jan 06

Instil Bio’s Subsidiary Discontinues Clinical Development of Axn-2510 and Terminates License and Collaboration Agreement With ImmuneOnco

THOMSON REUTERS
·
Jan 06

Junce Bio Focuses on "Lymphodepletion-Free" Breakthrough in Solid Tumors, GC101 Expected to Submit Marketing Application in 2026

Deep News
·
Dec 30, 2025

Junshi Biosciences Files for Hong Kong IPO: Core Product Shows Modest Data with Pending Patents, Pre-Listing Shareholder Repurchase Demands Raise Concerns

Deep News
·
Dec 17, 2025

EU Opens Probe Into TIL, CK Hutchison Barcelona Terminal Deal

Dow Jones
·
Dec 11, 2025

TIL Enviro Limited's (HKG:1790) Prospects Need A Boost To Lift Shares

Simply Wall St.
·
Nov 25, 2025

Instil Bio Q3 Adj. EPS $(1.75) Beats $(2.35) Estimate

Benzinga
·
Nov 13, 2025

Instil Bio Q3 net loss per share narrows

Reuters
·
Nov 13, 2025

Instil Bio Q3 Basic EPS USD -2.01

THOMSON REUTERS
·
Nov 13, 2025

Instil Bio Inc - Expects Cash to Fund Operations Beyond 2026

THOMSON REUTERS
·
Nov 13, 2025

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Nov 13, 2025